Synthetic Biscoumarin Analogs: Their PC3 Cell Line and Antioxidant Inhibitory Potentials

Clicks: 291
ID: 106280
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Prostate cancer is perhaps the most dominant cancer in men. The increased resistance to therapeutic agents and deficiency of targeted therapy for prostate cancer cells offer motivation to find new scaffolds for the treatment. The current study investigates substituted biscoumarin analogs (1-19) anticancer activity in the prostate cancer (PC3) cell line and its antioxidant potential. Out of these nineteen analogs, the compounds 1, 8, 9, 10, 12, 14, 16, 18 and 19 showed good PC3 cell line inhibitory potential when compared with the standard doxorubicin. Compounds 1-19 were also checked for DPPH radical scavenging potential. Compounds 2, 5, and 17 showed good potential. All analogs were also evaluated for superoxide anion scavenging activity and found to be inactive. The docking analysis shows that the biscoumarin is an anti-cancer ligand and has the ability to inhibit the activity of the human histone acetyltransferase. Overall this study has contributed for anticancer and antioxidant agents.
Reference Key
Ullah2020JournalSynthetic Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hayat Ullah;Hayat Ullah;Fahad Khan;Fahad Khan;Imad Uddin;Imad Uddin;Fazal Rahim;Fazal Rahim;Muhammad Taha;Muhammad Taha;Khalid Zaman;Khalid Zaman;Aftab Ahmad Khan;Aftab Ahmad Khan;Fawad Ahmad;Fawad Ahmad;Zia Ur Rehman;Zia Ur Rehman;Fazal Suhrab Gul;Fazal Suhrab Gul;Mehran;Mehran;Nisar Ahmad;Nisar Ahmad;Mushtaq Ahmad;Mushtaq Ahmad;Muhammad Imran Fakhri;Muhammad Imran Fakhri;Khalid Mohammad Khan;Khalid Mohammad Khan;
Journal journal of ongoing chemical research
Year 2020
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.